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ABSTRACT
Multiple myeloma (MM)-associated osteolytic bone disease is a major cause 
of morbidity and mortality in MM patients and the development of new therapeutic 
strategies is of great interest. The proto-oncogene SRC is an attractive target for such 
a strategy. In the current study, we investigated the effect of treatment with the 
SRC inhibitor saracatinib (AZD0530) on osteoclast and osteoblast differentiation and 
function, and on the development of MM and its associated bone disease in the 5TGM.1 
and 5T2MM murine MM models. In vitro data showed an inhibitory effect of saracatinib 
on osteoclast differentiation, polarization and resorptive function. In osteoblasts, 
collagen deposition and matrix mineralization were affected by saracatinib. MM cell 
proliferation and tumor burden remained unaltered following saracatinib treatment 
and we could not detect any synergistic effects with drugs that are part of standard 
care in MM. We observed a marked reduction of bone loss after treatment of 
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parameters to levels observed in naive control mice. Histomorphometric analyses 
support that this occurs through an inhibition of bone resorption. In conclusion, 
these data further establish SRC inhibition as a promising therapeutic approach for 
the treatment of MM-associated osteolytic bone disease.
INTRODUCTION
Multiple myeloma (MM) is the second most 
common hematological malignancy and accounts for 
approximately 1% of all cancers and 2% of all deaths 
from cancer. In the past decades, therapeutic advances 
have been made by introducing hematopoietic stem 
cell transplantation and new targeted molecules such as 
immune-modulatory agents, proteasome inhibitors and 
monoclonal antibodies. Unfortunately, MM remains an 
incurable disease with a 10-year survival of approximately 
30% in patients under 60 years [1]. MM is characterized 
by the clonal proliferation and accumulation of malignant 
plasma cells in the bone marrow (BM), monoclonal serum 
protein and associated organ dysfunction [2]. Underlying 
these changes are the oncogenic transformation of plasma 
cells and an associated altered BM microenvironment that 
further supports MM development [3].
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A major cause of morbidity and mortality in MM 
is the development of bone destructive lesions due to 
osteolytic bone disease, which occurs in more than 
80% of MM patients. These lesions can be extensive 
and cause severe bone pain, hypercalcemia, spinal 
cord compression and pathologic fractures that require 
radiation or surgical intervention. It is estimated that 50% 
of patients develop pathologic fractures over the course 
of their disease, increasing the risk of death by more than 
20% compared to patients without fractures [4, 5]. MM-
associated osteolytic bone disease is characterized by 
increased osteoclastogenesis and suppression of osteoblast 
function. This occurs via multiple mechanisms, including 
the secretion of osteoclastogenic factors and osteoblast-
inhibitory factors by both MM cells and stromal cells 
in the MM microenvironment. As a result, the bone 
remodeling process is uncoupled culminating in bone loss 
and lytic lesions [6-8].
The proto-oncogene c-SRC (SRC), a member of the 
SRC family of protein tyrosine kinases (SFKs), is a non-
receptor tyrosine kinase that mediates signal transduction 
from a diverse set of cell surface receptors in a wide 
range of cellular processes, including proliferation, 
differentiation, motility, adhesion and survival [9, 10]. 
SRC has been suggested to play an equally important 
role in osteoclasts and osteoblasts. SRC levels increase 
during osteoclast differentiation and SRC is important 
for the formation of actin rings in mature osteoclasts 
[11, 12]. Contrary to osteoclasts, SRC levels appear to 
decrease during osteoblast differentiation [13, 14]. As a 






correspond with the osteopetrotic phenotype observed in 
SRC-/- mice [16], which display hepatosplenomegaly and 
develop odontomas with age [17].
As described, MM-associated osteolytic bone 
disease not only has a negative impact on the quality of 
life but also results in morbidity and adversely impacts 
overall survival of MM patients. Bisphosphonates remain 
the standard of care for MM-associated osteolytic bone 
disease and slow the progression of osteolytic lesions, 
prevent the development of pathologic fractures and may 
have additional limited anti-tumor effects in MM [18]. 
Interestingly, recent reports suggest that bisphosphonates 
act in part by inhibiting SRC expression [19] or modulating 
SRC signaling [20]. However, bisphosphonate use can 
have adverse side effects such as renal impairment, the 
development of atypical fractures and avascular necrosis 
of the jaw. Similar adverse effects were observed with 






denosumab [21]. Moreover, skeletal-related events 
still occur in approximately 25% of patients receiving 
bisphosphonate therapy [22]. Thus, the development 
of new therapeutic strategies for this MM-related bone 
disease is of great interest. SRC is a promising target 
for such a strategy, given its important role in osteoclast 
and osteoblast function. Saracatinib is an orally available 
ATP-competitive SRC inhibitor which has been shown 
to hamper osteoclast function. In the current study, we 
investigated the effect of saracatinib on osteoclast and 
osteoblast function, and on the development of MM and 
its associated osteolytic bone disease.
RESULTS
Expression of SRC family kinases in the multiple 
myeloma microenvironment
Saracatinib (Figure 1A) is a potent SRC inhibitor 
with an IC50 of 2.7 nM in cell-free assays [23]. Aside 
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cohort of MM patients (n = 162) at different stages of the 
	DW+Lyn, all SFKs are expressed at low levels 











of SFK protein levels in different MM cell lines, i.e. U266, 
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show very low to absent protein expression of SFKs in 












in Src expression during osteoclast differentiation, while 
Fgr expression levels moderately increased. Other SFKs 
were expressed at very low levels (Supplementary. Figure 
S1A). During the differentiation from mesenchymal stem 
cells to fully differentiated osteoblasts, Fyn expression 
levels slightly increased. Conversely, Src"!
decreased at day 14, followed by a return to initial levels 
in fully matured osteoblasts at day 21. Osteoblasts also 
expressed Yes and Lyn (Supplementary. Figure S1B).
Saracatinib inhibits RAW264.7 and primary 
osteoclast differentiation and bone resorption
Saracatinib treatment has previously been linked 
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inhibitory effect of saracatinib on osteoclast generation by 




decrease in the number of osteoclasts, i.e. TRAP-positive 
cells with at least 3 nuclei, which already became apparent 
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stimulated cultures. Src, Nfatc1 and Trap expression levels 
were not affected by saracatinib (Figure 2F). Conversely, 
saracatinib treatment resulted in a decreased expression of 
Ctsk and Dc-stamp and an increased expression of Mmp-9 
compared to DMSO-treated osteoclast cultures (Figure 2F). 
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saracatinib treatment, even though osteoclasts displayed a 
normal morphology at this concentration, and a complete 


















Saracatinib decreases collagen deposition and 
affects matrix mineralization by osteoblasts
V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osteoblast function has not yet been explored. 






differentiation and function [24], and on primary murine 






cells is hampered when treated with pharmacologically 
relevant saracatinib concentrations, i.e. a decrease of 
31% relative absorbance on day 14 with a concentration 




















matrix mineralization by Sirius red staining and Von 
Kossa staining, respectively (Figure 3C). Osteoblast 
size appeared increased in saracatinib-treated cultures 
and coincided with drastically decreased collagen 
deposition (Figure 3D). The total degree of matrix 
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mineralization appeared different in saracatinib-treated 
cultures with less discerned nodules. Conversely, 
matrix mineralization markedly increased in MSC 
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migration (Figure 3F). Finally, we assessed the effect 
of saracatinib on osteoblast marker gene expression 
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and Ocn expression. In addition, Col1a1 expression 
was diminished, although this did not reach statistical 
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proliferation or bone marrow plasmocytosis in 
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myeloma cell lines and murine 5T33 cell proliferation was 
Figure 3: Effect of saracatinib on osteoblast function. A.>		*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not affected by saracatinib (Supplementary. Figure S2). 
Thus, saracatinib has no effect on MM cell proliferation at 









studies in which saracatinib was combined with drugs 
that are part of standard care for MM, i.e. bortezomib, 
lenalidomide and dexamethasone. Similarly, we could 
observe no additive or synergistic effects when combining 
saracatinib with these drugs (Figure 4A and Supplementary. 
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6.67%) (Figure 4C). In addition, there was no difference 
in spleen weight between saracatinib- and vehicle-treated 
mice (Figure 4D). In the 5T2MM model, daily treatment 
was initiated 5 weeks after injection of 5T2MM cells 






could be detected in the serum of diseased mice and the 
treatment schedule corresponds to the clinical situation 











conclusion, saracatinib did not hamper the proliferation 
of MM cells in the BM. Of note, we observed an almost 
complete absence of any sign of paraplegia, caused by 









improved bone strength in these mice.
Figure 4: Effect of saracatinib, and combinations with standard drugs, on multiple myeloma cell proliferation, and bone 
marrow plasmocytosis. A. > 		* 
 N> *
































































Saracatinib treatment limits the development 
of osteolytic bone disease in the 5TGM.1 and 
5T2MM multiple myeloma models
The effect of saracatinib treatment on trabecular 
and cortical bone parameters in myeloma-bearing mice 
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in a decrease in the number (Figure 5B) and size (Figure 
5C) of cortical perforations. Although perforations were 
observed in every portion of the bone, they predominantly 
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bone parameters (Figure 5D) and found that trabecular 
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observed in naive control mice following saracatinib 
treatment. In addition, connectivity density (Conn.Dn) 
(Figure 5I) values were restored. Conversely, there was 
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it did not reach the level of that observed in healthy mice. 
The marrow area, endosteal and periosteal perimeter were 
lower in MM bearing mice and saracatinib treatment did 
not affect these parameters (Supplementary. Figure S3A).
In the 5T2MM model there was no effect of 
saracatinib treatment on the number (Figure 6B) or size 






the metaphyses. However, even though the osteolytic 
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to vehicle-treated controls. In this model, the restoration 
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restored and Conn.Dn (Figure 6I) was not affected by 
saracatinib treatment. Similar to the occurrence of cortical 









no differences in porosity, marrow area, periosteal and 
endosteal perimeter between vehicle- and saracatinib-
treated myeloma-bearing mice (Supplementary. Figure 
S3B).











7B) and TRAP stainings (Figure 7C) were performed to 
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controls. Consistent with our in vitro data, saracatinib 
treatment did not result in a restoration of either of these 












have been made in recent years, MM remains an incurable 
hematological malignancy associated with high morbidity 
and mortality related to osteolytic bone disease. The 
characteristic bone loss and lytic lesions are caused by 





osteoclast biology and has been implicated in osteoblast 
differentiation makes SRC a promising target for the 
treatment of MM-associated osteolytic bone disease.
SRC is constitutively expressed at high levels only 
in cells that are specialized for regulated secretion, i.e. 
neuronal cells, platelets and osteoclasts [10, 25]. Also, 
SRC is predominantly maintained in an inactive state 
in normal cells. Conversely, SRC levels or activity are 
increased in many types of cancer and SRC modulates 
several aspects of tumorigenesis, including tumor 
cell adhesion, migration, motility and survival [26]. 
This spurred the development of a wide range of SRC 
inhibitors, several of which are currently in clinical 
trials or are already approved for cancer therapy [26, 
27]. Saracatinib is an orally available ATP-competitive 
SRC (IC50: 2.7 nM) inhibitor that also potently inhibits 
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30nM) [23]. Although less potent in cell-free assays 
than inhibitors such as dasatinib, saracatinib has a higher 
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inhibition of the SRC signaling pathway in human tumor 
tissue [28]. Moreover, initial studies indicate saracatinib is 
generally well-tolerated [29-31].
Osteoclast differentiation as well as their activity 
is increased in the MM microenvironment. This is 
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colony-stimulating factor (M-CSF), which are secreted 
both by MM and stromal cells [6, 32]. SRC levels are 







 integrin, resulting in osteoclast 
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[33, 34]. De Vries et al. demonstrated that saracatinib 
reduces phosphorylated SRC levels in human osteoclast 
cultures, resulting in a reduced osteoclast differentiation 
Oncotarget8www.impactjournals.com/oncotarget
Figure 5: Effect of saracatinib treatment on the development of bone disease in the 5TGM.1 multiple myeloma model.
A. Representative distal femur radiographs of naive control mice, vehicle-treated myeloma-bearing mice and saracatinib (S)-treated myeloma-























right panels show a lateral view. E.		

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F. 		"&/G. trabecular thickness (Tb.Th), H.







bones, *: p<.0.05, **: p<0.01, ***: p<0.001). J. Representative reconstructed 3D-models of cortical bone of the distal femur in naive control 
mice, vehicle-treated mice and saracatinib-treated mice. K.:
	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








Figure 6: Effect of saracatinib treatment on the development of bone disease in the 5T2MM multiple myeloma model. A.
Representative distal femur radiographs of naive control mice, vehicle-treated myeloma-bearing mice and saracatinib (S)-treated myeloma-






















show a lateral view. E.		

OGO&/F.		"&/G. trabecular thickness (Tb.Th), H. trabecular 








, *: p<.0.05, **: p<0.01). J. Representative reconstructed 3D-models of cortical bone of the distal femur in naive control mice, vehicle-treated 












Figure 7: Histomorphometric analysis of bone parameters in the 5TGM.1 multiple myeloma model. A. Representative 
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C. Representative images of 
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reports [35-37], we observed an inhibition of osteoclast 
differentiation, polarization and matrix resorption 
following SRC inhibition, which corresponded with a 
decrease in cathepsin K (Ctsk&@
/L>
saracatinib almost completely blocked matrix resorption. 
Also, saracatinib induced a decrease in dendrocyte 
expressed seven transmembrane protein (DC-Stamp) 
expression and an increase in matrix-metalloproteinase 
9 (Mmp9) expression, suggesting these osteoclasts are 
stuck in a pre-fusion state, with the presence of many 
pseudopodia, since DC-STAMP mediates osteoclast 
progenitor fusion [38] and, although not yet studied in the 
context of osteoclastogenesis, MMP9 has been implicated 
in the migration of monocytes [39, 40] and accumulates 
at the leading edge of pseudopodia [41, 42]. Defective 
osteoclast function after saracatinib treatment is in 
	Y+	Z	Q	
et al. 
reported a decrease in bone resorption markers in healthy 
men and in patients with diverse advanced malignancies 
after saracatinib treatment [29, 30]. In addition, osteoclast 
function is impaired in Src'G'_/Y+	*	




Osteoblast differentiation is suppressed in the 
MM microenvironment [6] and SRC protein levels have 
previously been shown to decrease during osteoblast 


















SRC in osteoblasts remains to be studied. Decreased Src 
expression inhibits immature osteoblast proliferation but 
enhances osteoblast differentiation, with a corresponding 















could not be solely attributed to a decrease in osteoblast 
numbers (Figure 3). Similarly, matrix mineralization 
pattern or amount was affected by saracatinib. 
Interestingly, a similar large increase in von Kossa staining 
intensity was observed previously in SRC-knockdown 
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migration, which corresponds with an inverse correlation 
between osteoblast migration and differentiation [45, 
46]. It is currently not clear by which mechanism SRC 
inhibition leads to these effects and further studies are 










osteoblasts in an immature state [14]. Multiple studies 
have reported an altered expression of osteoblast markers 
following SRC depletion or inhibition [13, 15, 44]. Here, 
we show that saracatinib treatment did not alter Src, Alp 







than expression [47]. On the other hand, osterix (Osx), 
which has been implicated in the regulation of alpha-1 
type 1 collagen (COL1A1) transcription [48], osteocalcin 
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at pharmacological relevant concentrations on the 
proliferation of murine and human MM cell lines, which 
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expression [50-52]. In addition, we found no additive or 
synergistic effects of saracatinib when combined with 
bortezomib, lenalidomide or dexamethasone (Figure 4 and 
Supplementary. Figure S2). This is contrary to dasatinib, 
which had minimal single agent activity in a phase 2 trial 
[53], but displayed synergy with bortezomib, melphalan 
en thalidomide in preclinical studies [54]. In vivo, when 
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bone metastasis, where SRC is critical for the survival and 
outgrowth of malignant cells in the BM [55].
"W/ Y 	   
 			 

the development of MM-associated osteolytic bone 
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5T2MM model we observed a marked prevention of 
bone loss after saracatinib treatment, with trabecular 
bone volume and number restored to levels observed in 
healthy mice. Trabecular thickness and separation were 
differentially affected during MM development in the 
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^>>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different development rate of MM as well as the different 
dependency of MM cells on, and thus interactions with, 
the BM microenvironment in these models. This could 
also explain the difference in both the number and size of 
cortical lesions during MM development in both models. 
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the number and size of cortical perforations and partially 
restored cortical thickness. However, saracatinib did not 
have such an effect in the 5T2MM model while other 
therapeutic strategies, both directed at inhibiting osteoclast 
activity [56, 57] or at promoting osteoblast differentiation 
[58], did. This is unlikely due to the delay in the start of 
treatment of these mice, considering serum paraprotein 
levels start to increase at 7-8 weeks in the 5T2MM 
Oncotarget12www.impactjournals.com/oncotarget
model after which osteolytic bone disease develops [59]. 
Alternatively, the treatment time could have been too short 
to observe effects on cortical bone given its remodeling 
rate is slower compared to trabecular bone. Finally, we 
performed histomorphometrical analyses (Figure 7). 
Saracatinib did not prevent the reduced bone formation 
observed in myeloma-bearing mice. Of note, the decreased 
collagen secretion following saracatinib treatment we 
observed in vitro did not result in a further decrease in 
osteoid surface in vivo @  	  	






osteoblasts by factors such as DKK-1 and sclerostin. Both 
osteoclast surface and numbers did not differ between 




a decrease in these 2 parameters in saracatinib- compared 









and thus osteoclastogenesis, between individual mice. 
In addition, this could be explained by a compensatory 
mechanism in the BM microenvironment that is not 





bone matrix resorption while osteoclast differentiation 
capacity is maintained in this more complex setting.
Although previous studies support a strong 
interdependency between MM cells and osteoclast activity 
[6, 60], we did not observe a decrease in tumor burden 
following saracatinib treatment in either model even 
though bone loss was prevented. This is in agreement 









the 5T2MM models [56, 58]. Conversely, other studies 
do report anti-MM effects following successful treatment 
of bone disease [5, 63-65]. Thus, additional studies 
are needed to further elucidate the interplay between 
osteolytic bone disease and MM tumor growth and to 
distinguish between direct and indirect effects.
This study further establishes SRC inhibition as a 
promising approach for the treatment of MM-associated 








results in a prevention of bone loss in 2 murine MM 
models. Additional clinical trials with SRC inhibition 








treatment of cancer-induced bone pain. Bone turnover will 
be assessed as a secondary outcome measure in this trial. 
Our study warrants direct evaluation of bone parameters 
and disease progression in MM patients treated with 
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studies, saracatinib was dissolved in a 0.5% 
hydroxypropylmethylcellulose solution containing 0.1% 
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vehicle solution by oral gavage. For in vitro studies, a 
stock solution was prepared at 10 mM in tissue-culture 
grade dimethylsulfoxide (Sigma-Aldrich).
Cell lines culture
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). Unless otherwise indicated all cell lines were 
purchased from ATCC (Molsheim, France).




data was carried out to examine the expression of 
SFKs targets of saracatinib in MM patients and healthy 
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expression in MM patients was supplemented with 
publically available data on protein expression in MM cell 
lines (www.proteinatlas.org) [69].
In vitro osteoclast differentiation, TRAP staining 
and actin staining
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monocytes were re-seeded on day 4 at a density of 6500 
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(Prepotech) was added to the culture medium to induce 












differentiation medium was refreshed and on day 4 the 


















was assessed by staining cultures with phalloidin-FITC 
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medium was refreshed every 3 days. After 12 days, a Von 
Kossa staining was performed to visualize non-resorbed 




In vitro osteoblast differentiation
Primary murine BM derived MSCs were isolated 
as described previously [70] and seeded at a density of 
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differentiation. The differentiation medium was refreshed 


























reagent was added to each well and incubated overnight at 






Osteoblast wound healing assay
To assess cell migration after treatment with 
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rates were calculated using linear regression analysis and 
determination of the slope.
RNA extraction, cDNA synthesis and real-time 
PCR
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with random hexamer primers using the Transcriptor 
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were as follows: 3 min at 95°C, 40 cycles of 10 s at 
95°C, 30 s at 60°C and 1 s at 75°C followed by a melting 
curve analysis. Measurements were performed at least in 





Von Kossa and Sirius red staining
Von Kossa staining was performed to detect 
mineralized matrix nodules in the osteoclast resorption 
assay and in osteoblast cultures. Cultures were 
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^L>"Q
4
OH (Sigma-Aldrich) for 
30 minutes at room temperature. After rinsing, plates were 
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Y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3
 (Sigma-Aldrich) solution for 1 
hour, rinsed, and incubated with 1% pyrogallol (Sigma-
Oncotarget14www.impactjournals.com/oncotarget
Aldrich) solution for 10 minutes at room temperature in 




rinsed and stained with 0.1% direct red (Sigma-Aldrich) 
in picric acid (Sigma-Aldrich) solution for 1 hour at room 
temperature. Both Von Kossa and Sirius red staining were 
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The 5TGM.1 and 5T2MM murine multiple 
myeloma models






from 5T33MM cells [74]. The in vivo growing 5T2MM 






KalwRij mice were purchased from Harlan (Horst, the 




tap water and they were housed and treated following 
conditions approved by the ethical committee for animal 
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over the course of 30 days after i.v. injection of 2.5x105 
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the occurrence of severe osteolytic lesions. In these mice, 
plasmacytosis was determined by staining cytosmears of 
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Treatment of multiple myeloma-bearing mice 
with saracatinib
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oral gavage starting at day one after injection. Six male 
mice were included as naive tumor-free controls. For the 
5T2MM cohort, 22 female mice were injected at 8 weeks 
old and divided in a vehicle-treated myeloma-bearing 





treatment was started at 5 weeks post-injection when a 
paraprotein could be detected by serum electrophoresis. 
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2. Images were captured every 0.4 degrees 






software (Bruker). Morphometric 3D analysis of 
trabecular bone was performed on proximal tibias on a 
1.5 mm section starting 0.5 mm from the growth plate 
using CTAnalyzer software (Bruker, version 1.14.4.1). 
Morphometric 2D and 3D analysis of cortical bone was 
performed in distal femurs on a 0.5 mm section starting 
3 mm from the growth plate. 3D images of bones were 
generated using CTVol software (Bruker). The number of 
cortical perforations was counted manually and blinded 
on radiographs.
Bone histomorphometry






were dehydrated in ascending alcohol concentrations, 
defatted in xylene and embedded in methylmethacrylate. 
All histomorphometric parameters were recorded as 






Committee [76] and measured using the Bonolab 
software package designed for bone histomorphometry 
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osteoblast surface were measured on sections stained 
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trichrome (Sigma-Aldrich). Osteoclasts were detected 
by tartrate-resistant acid phosphatase (TRAP) staining 
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
acid phosphatase using naphthol ASTR phosphate 
as substrate in the presence of 50 mM tartrate with 
hexazotised pararosaline, and counterstained with 
methyl green. TRAP-positive cells were counted in the 
whole epiphysis (×25), and expressed as the number 








and representative pictures are shown. For comparisons 
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